Quiet Biology
Phase 04, Progressive

Active

The disease is moving, decisions made now shape everything that follows.

The disease is moving, and the decisions made now, about what to treat, how, and in what sequence, will shape everything that follows.

Foundational papers

3 papers. Why they matter here.

  1. Paper 1

    Tumour Ecology and Evolutionary Stability

    Read the paper →

    Why aggressive disease arises from ecological collapse, and how treatment decisions affect the evolutionary trajectory that follows.

  2. Paper 2

    Cancer as an Ecological and Evolutionary System

    Read the paper →

    Adaptive therapy. Why managing the tumour ecosystem produces better evolutionary outcomes than attempting to eliminate it.

  3. Paper 3

    PSA Kinetics and the Natural History of Prostate Cancer

    Read the paper →

    PSA kinetics as the real-time window into biological momentum. Distinguishing genuine acceleration from noise.

Framework papers

11 papers. Why they matter here.

  1. Paper 1

    The Three Layers of Intervention

    Read the paper →

    The full depth model. Why active disease requires coordinated action across output, signalling, and structural layers simultaneously.

  2. Paper 2

    Signal, Stress, and Selection

    Read the paper →

    The sequencing architecture for active disease. How to apply pressure without accelerating the resistance it is trying to prevent.

  3. Paper 3

    Dynamic Fitness Landscapes and Evolutionary Constraint in Prostate Cancer

    Read the paper →

    Why continuous maximal pressure selects for resistance, and why oscillating treatment environments prevent tumour populations from reaching stable adaptive optima. The evolutionary rationale for sequencing.

  4. Paper 4

    From Intervention to Environment

    Read the paper →

    Why the sequence of interventions, not any individual agent, is the mechanism at this phase.

  5. Paper 5

    Rapamycin, mTOR Oscillation, and the p53-MDM2 Axis

    Read the paper →

    Maintaining quality-control rhythm under active disease conditions.

  6. Paper 6

    MDM2 as Convergence Point

    Read the paper →

    The convergence point argument in the context of active disease, what addressing the upstream metabolic environment still achieves.

  7. Paper 7

    Doxycycline: Multi-Pillar Analysis

    Read the paper →

    The four convergent mechanisms and their relevance to active disease management.

  8. Paper 8

    Testosterone, p53, and the MDM2 System

    Read the paper →

    Preserving AR dependence during active disease. The saturation model and its implications for treatment sequencing.

  9. Paper 9

    Oestrogen's Role in Prostate Cancer

    Read the paper →

    The four oestrogen mechanisms as active drivers of progressive disease, and what addressing them achieves.

  10. Paper 10

    Sirtuins, NAD⁺, and the Quiet Biology Framework

    Read the paper →

    The SIRT1 axis as a parallel control layer during active disease management.

  11. Paper 11

    A Hierarchy of Biological Signals

    Read the paper →

    Phase 4 spans Levels 3 and 4, functional shift and phenotype expression. The monitoring objective shifts to detecting PSA-biology decoupling before it becomes a signal failure.